Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 18/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.64 |
| ▸ | ACACB | O00763 | 1/20 | 0.55 |
| ▸ | ACACA | Q13085 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9047623 | 0.91 | ACACB (0.55) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9055523 | 0.89 | ACACB (0.65) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9045275 | 0.88 | ACACB (0.53) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9047637 | 0.84 | ALOX5 (0.65) | ALOX5EPHX2ACACBACACAMAPT | |
| SCHEMBL9046363 | 0.83 | ALOX5 (0.55) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9048145 | 0.83 | ALOX5 (0.59) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL8883050 | 0.82 | ALOX5 (0.72) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL8883053 | 0.82 | ALOX5 (0.72) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9049700 | 0.81 | ALOX5 (0.53) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL8308830 | 0.79 | ALOX5 (0.64) | ALOX5EPHX2ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0731688-B1 | AEROSOL DRUG FORMULATIONS FOR USE WITH NON-CFC PROPELLANTS | ABBOTT LAB (US) | 2003-03-05 | — | — | EP | claimed |
| US-5676931-A | DRUG DELIVERY | ABBOTT LABORATORIES (US) | 1997-10-14 | — | — | US | claimed |
| EP-0731688-A1 | AEROSOL DRUG FORMULATIONS FOR USE WITH NON-CFC PROPELLANTS | Abbott Laboratories (US) | 1996-09-18 | — | — | EP | claimed |
| WO-1995015151-A1 | AEROSOL DRUG FORMULATIONS FOR USE WITH NON-CFC PROPELLANTS | ABBOTT LABORATORIES (US) | 1995-06-08 | — | — | WO | claimed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| EP-0731688-B1 | AEROSOL DRUG FORMULATIONS FOR USE WITH NON-CFC PROPELLANTS | ABBOTT LAB (US) | 2003-03-05 | — | — | EP | disclosed |
| US-5676931-A | DRUG DELIVERY | ABBOTT LABORATORIES (US) | 1997-10-14 | — | — | US | disclosed |
| EP-0540673-B1 | ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LAB (US) | 1996-10-16 | — | — | EP | disclosed |
| US-5559144-A | LIPOXYGENASE INHIBITORS, INHIBITORS OF BIOSYNTHESIS OF LEUKOTRIENES | ABBOTT LABORATORIES (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0731688-A1 | AEROSOL DRUG FORMULATIONS FOR USE WITH NON-CFC PROPELLANTS | Abbott Laboratories (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5476873-A | Inhibit biosynthesis of leukotrienes | ABBOTT LABORATORIES (US) | 1995-12-19 | — | — | US | disclosed |
| WO-1995015151-A1 | AEROSOL DRUG FORMULATIONS FOR USE WITH NON-CFC PROPELLANTS | ABBOTT LABORATORIES (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | ALOX5 25/4885EPHX2 122/4885ACACB 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.